New Service for Circulating Tumor Cell Analysis Now Available
|
By LabMedica International staff writers Posted on 18 Feb 2014 |
|
Image: Fluxion’s IsoFlux system with cutting-edge technology for circulating tumor cell enrichment (Photo courtesy of Fluxion Bioscences).
A new clinical sample procurement capability, including fresh blood draws from a wide range of cancer indications and tumor subtype profiles, improves circulating tumor cell analysis services.
The cutting-edge technology of the IsoFlux system for circulating tumor cell (CTC) enrichment and analysis is among the systems from Fluxion Biosciences (South San Francisco, CA, USA) designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. Fluxion now also has the new capability to include full-service clinical sample procurement to expand its IsoFlux Discovery Services offering. Fluxion has been providing a broad range of analytic services using its IsoFlux system for CTC enrichment, including quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS)-based assays. With this new capability, Fluxion can now also provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.
The services are available to diagnostic, biopharmaceutical, and research institutes that wish to conduct CTC studies with clinical samples on a contract basis. These are provided out of Fluxion’s South San Francisco reference laboratory using cutting-edge IsoFlux technology as well as the CTC experience of Fluxion scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under Institutional Review Board (IRB) consent.
“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, program director at Fluxion; “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”
Related Links:
Fluxion Biosciences
Isoflux
 (3) (1).png)
The cutting-edge technology of the IsoFlux system for circulating tumor cell (CTC) enrichment and analysis is among the systems from Fluxion Biosciences (South San Francisco, CA, USA) designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. Fluxion now also has the new capability to include full-service clinical sample procurement to expand its IsoFlux Discovery Services offering. Fluxion has been providing a broad range of analytic services using its IsoFlux system for CTC enrichment, including quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS)-based assays. With this new capability, Fluxion can now also provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.
The services are available to diagnostic, biopharmaceutical, and research institutes that wish to conduct CTC studies with clinical samples on a contract basis. These are provided out of Fluxion’s South San Francisco reference laboratory using cutting-edge IsoFlux technology as well as the CTC experience of Fluxion scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under Institutional Review Board (IRB) consent.
“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, program director at Fluxion; “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”
Related Links:
Fluxion Biosciences
Isoflux
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Pipette
Accumax Smart Series
New
Rapid Molecular Testing Device
FlashDetect Flash10
Latest Technology News
- Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
- Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
- Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes
- Wireless Sweat Patch Could Be Used as Diagnostic Test for Cystic Fibrosis
- New Method Advances AI Reliability with Applications in Medical Diagnostics
- Self-Powered Microneedle Patch Collects Biomarker Samples Without Drawing Blood
- Skin Patch Detects Biomarkers in Interstitial Fluid Without Blood Draws
- Handheld Saliva Test Accurately Detects Breast Cancer
- Cutting-Edge AI Algorithms Enable Early Detection of Prostate Cancer
- New Microfluidic System Enables Early Cancer Diagnosis Using Simple Blood Tests
Channels
Clinical Chemistry
view channel
Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. Current approaches make it difficult to accurately... Read more
Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more
Molecular Diagnostics
view channel
2-Hour Cancer Blood Test to Transform Tumor Detection
Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more
Automated High Throughput Immunoassay Test to Advance Neurodegenerative Clinical Research
Alzheimer’s disease and other neurodegenerative disorders remain difficult to diagnose and monitor accurately due to limitations in existing biomarkers. Traditional tau and phosphorylated tau measurements... Read more
Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients
HR+ (hormone receptor-positive) HER2- (human epidermal growth factor receptor 2-negative) breast cancer represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.... Read more
Hematology
view channel
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more
Immunology
view channel
Novel Tool Uses Deep Learning for Precision Cancer Therapy
Nearly 50 new cancer therapies are approved each year, but selecting the right one for patients with highly individual tumor characteristics remains a major challenge. Physicians struggle to navigate the... Read more
Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more
Microbiology
view channel
Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Sepsis arises from infection and immune dysregulation, with neutrophils playing a central role in its progression. However, current clinical tools are unable to both isolate these cells and assess their... Read more
New Diagnostic Method Confirms Sepsis Infections Earlier
Sepsis remains one of the most dangerous medical emergencies, often progressing rapidly and becoming fatal without timely intervention. Each hour of delayed treatment in septic shock reduces patient survival... Read more
New Markers Could Predict Risk of Severe Chlamydia Infection
Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
Vaginal health depends on maintaining a balanced microbiome, particularly certain Lactobacillus species. Disruption of this balance, known as dysbiosis, can increase risks of infection, pregnancy complications,... Read morePathology
view channel
Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma
Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Clinicopathologic Study Supports Exclusion of Cervical Serous Carcinoma from WHO Classification
High-grade serous carcinoma is a rare diagnosis in cervical biopsies and can be difficult to distinguish from other tumor types. Cervical serous carcinoma is no longer recognized as a primary cervical... Read more
Industry
view channel
VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies
VedaBio (San Diego, CA, USA) has entered into a non-exclusive license agreement with Mammoth Biosciences (Brisbane, CA, USA) for the use of select CRISPR-based technologies in diagnostic applications.... Read more
